Compare LTGO & DEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LTGO | DEC |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2026 | 2022 |
| Metric | LTGO | DEC |
|---|---|---|
| Price | $14.08 | $14.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $52.25 | $21.13 |
| AVG Volume (30 Days) | 359.2K | ★ 722.9K |
| Earning Date | 11-19-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 7.81% |
| EPS Growth | N/A | ★ 311.06 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $1,829,142,000.00 |
| Revenue This Year | N/A | $26.85 |
| Revenue Next Year | N/A | $19.24 |
| P/E Ratio | ★ N/A | $13.04 |
| Revenue Growth | N/A | ★ 141.54 |
| 52 Week Low | $14.60 | $12.33 |
| 52 Week High | $25.93 | $18.90 |
| Indicator | LTGO | DEC |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 58.93 |
| Support Level | N/A | $14.60 |
| Resistance Level | $20.49 | $14.95 |
| Average True Range (ATR) | 1.23 | 0.37 |
| MACD | -0.21 | 0.13 |
| Stochastic Oscillator | 1.69 | 83.35 |
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
Diversified Energy Co engaged in the production, transportation, and marketing of natural gas, NGLs, and oil, managing a diversified portfolio of mature, long-life assets located across the United States. The company derives revenues from the sale of oil, natural gas and natural gas liquids.